2017年5月,FDA扩展批准托珠单抗皮下注射剂(Actemra)用于治疗巨细胞动脉炎成年患者。巨细胞动脉炎是成人最常见的系统性血管炎。这种炎症可导致动脉狭窄或变得不规则,阻碍充分的血流。巨细胞动脉炎多涉及头部血管,特别是颞动脉。鉴于这个原因,该疾病有时也称颞动脉炎。本品用于巨细胞动脉炎治疗的有效性与安全性基于一项由251例巨细胞动脉炎患者参与的双盲、安慰剂 In May 2017, the FDA expanded the approval of Actemra for treatment of adult patients with giant cell arteritis. Giant cell arteritis is the most common systemic vasculitis in adults. This inflammation can lead to stenosis or irregularities in the arteries, hindering adequate blood flow. Giant cell arteritis involves the blood vessels in the head, especially the temporal arteries. For this reason, the disease is sometimes called temporal arteritis. This product for the treatment of giant cell arteritis effectiveness and safety based on a 251 patients with giant cell arteritis patients involved in double-blind, placebo